BIOMAT Database Logo BIOMAT Database Logo

A comparison of androgen status in patients with prostatic cancer treated with oral and/or parenteral estrogens or by orchidectomy. 1989

K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
Department of Obstetrics and Gynecology, Karolinska Institutet, Huddinge University Hospital, Sweden.

The effects of orchidectomy, combined oral/parenteral estrogen, and single-drug parenteral estrogen therapy on the serum levels of testosterone (T), 4-androstene-3,17-dione (A-4), dehydroepiandrosterone (DHA) and its sulfate (DHAS), sex-hormone-binding globulin (SHBG), and albumin were studied in 48 patients with prostatic cancer. Both estrogen treatment regimens were as effective as orchidectomy in reducing circulating levels of T and A-4. Orchidectomy caused a slight decrease in DHAS levels. Oral estrogens profoundly decreased the serum levels of DHAS and, to a lesser extent, levels of DHA and of albumin, while parenteral estrogens had no effect in this respect. SHBG serum levels were highly increased by oral estrogens, slightly increased by parenteral estrogens, and unaffected by orchidectomy. The more pronounced effects of oral estrogens on circulating adrenal androgens may reflect an altered liver metabolism associated with this route of administration.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009919 Orchiectomy The surgical removal of one or both testicles. Castration, Male,Orchidectomy,Castrations, Male,Male Castration,Male Castrations,Orchidectomies,Orchiectomies
D011471 Prostatic Neoplasms Tumors or cancer of the PROSTATE. Cancer of Prostate,Prostate Cancer,Cancer of the Prostate,Neoplasms, Prostate,Neoplasms, Prostatic,Prostate Neoplasms,Prostatic Cancer,Cancer, Prostate,Cancer, Prostatic,Cancers, Prostate,Cancers, Prostatic,Neoplasm, Prostate,Neoplasm, Prostatic,Prostate Cancers,Prostate Neoplasm,Prostatic Cancers,Prostatic Neoplasm
D003687 Dehydroepiandrosterone A major C19 steroid produced by the ADRENAL CORTEX. It is also produced in small quantities in the TESTIS and the OVARY. Dehydroepiandrosterone (DHEA) can be converted to TESTOSTERONE; ANDROSTENEDIONE; ESTRADIOL; and ESTRONE. Most of DHEA is sulfated (DEHYDROEPIANDROSTERONE SULFATE) before secretion. Dehydroisoandrosterone,Prasterone,5-Androsten-3-beta-hydroxy-17-one,5-Androsten-3-ol-17-one,Androstenolone,DHEA,Prasterone, 3 alpha-Isomer,5 Androsten 3 beta hydroxy 17 one,5 Androsten 3 ol 17 one,Prasterone, 3 alpha Isomer
D004967 Estrogens Compounds that interact with ESTROGEN RECEPTORS in target tissues to bring about the effects similar to those of ESTRADIOL. Estrogens stimulate the female reproductive organs, and the development of secondary female SEX CHARACTERISTICS. Estrogenic chemicals include natural, synthetic, steroidal, or non-steroidal compounds. Estrogen,Estrogen Effect,Estrogen Effects,Estrogen Receptor Agonists,Estrogenic Agents,Estrogenic Compounds,Estrogenic Effect,Estrogenic Effects,Agents, Estrogenic,Agonists, Estrogen Receptor,Compounds, Estrogenic,Effects, Estrogen,Effects, Estrogenic,Receptor Agonists, Estrogen
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations
D000368 Aged A person 65 years of age or older. For a person older than 79 years, AGED, 80 AND OVER is available. Elderly
D000728 Androgens Compounds that interact with ANDROGEN RECEPTORS in target tissues to bring about the effects similar to those of TESTOSTERONE. Depending on the target tissues, androgenic effects can be on SEX DIFFERENTIATION; male reproductive organs, SPERMATOGENESIS; secondary male SEX CHARACTERISTICS; LIBIDO; development of muscle mass, strength, and power. Androgen,Androgen Receptor Agonist,Androgen Effect,Androgen Effects,Androgen Receptor Agonists,Androgenic Agents,Androgenic Compounds,Agents, Androgenic,Agonist, Androgen Receptor,Agonists, Androgen Receptor,Compounds, Androgenic,Effect, Androgen,Effects, Androgen,Receptor Agonist, Androgen,Receptor Agonists, Androgen

Related Publications

K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
Bone mineral density in patients with prostatic cancer treated with orchidectomy and with estrogens.
August 1995, Calcified tissue international,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
Plasma lipoproteins during anti-androgen treatment by estrogens or orchidectomy in men with prostatic carcinoma.
May 1981, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
Activators and inhibitors of coagulation and fibrinolysis in patients with prostatic cancer treated with oestrogen or orchidectomy.
December 1986, Thrombosis research,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
Serum prolactin assays have no prognostic value in treatment of prostatic cancer by orchidectomy or estrogens.
January 1987, Urologia internationalis,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
Cost-effectiveness comparison of estrogen therapy and orchidectomy in patients with prostatic cancer.
January 1987, International journal of technology assessment in health care,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
[The outcome of prostatic cancer treated with estrogens].
July 1973, Acta urologica Belgica,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
[Histologic aspect of a prostatic cancer treated by testicular enucleation and estrogens].
October 1953, Journal belge d'urologie,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
Cost comparison of parenteral estrogen and conventional hormonal treatment in patients with prostatic cancer.
January 1991, International journal of technology assessment in health care,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
Cardiovascular and all-cause mortality in prostatic cancer patients treated with estrogens or orchiectomy as compared to the standard population.
January 1991, The Prostate,
K Carlström, and L Collste, and A Eriksson, and P Henriksson, and A Pousette, and R Stege, and B von Schoultz
[Hormonal status in patients with advanced prostatic cancer on the therapy with androgen blockade].
April 2011, Vojnosanitetski pregled,
Copied contents to your clipboard!